/ABEO
ABEO Stock - Abeona Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$5.11+3.86%
+$0.19 (+3.86%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.42
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.75
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+252.3%upside
Target: $18.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ABEO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.06 – $5.16
TARGET (TP)$18.00
STOP LOSS$4.70
RISK/REWARD1:31.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.11
52W High$7.54
52W Low$3.93
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $3.50M | $1.41M | $3.00M | $10.00M |
| Gross Profit | $-2,907,000 | $1.90M | $964,000 | $3.00M | $10.00M |
| Gross Margin | N/A | 54.1% | 68.2% | 100.0% | 100.0% |
| Operating Income | $-64,211,000 | $-47,135,000 | $-50,915,000 | $-89,836,000 | $-81,420,000 |
| Net Income | $-63,734,000 | $-54,188,000 | $-39,696,000 | $-84,936,000 | $-84,234,000 |
| Net Margin | N/A | -1548.2% | -2807.4% | -2831.2% | -842.3% |
| EPS | $-1.55 | $-2.53 | $-5.53 | $-21.50 | $-22.75 |
Company Overview
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$18
Average Target
↑ 247.4% Upside
Now
$15
Low
$18
Average
$21
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 2nd 2025 | Oppenheimer | Resumed | Outperform | $19 |
| March 5th 2025 | Oppenheimer | Initiation | Outperform | $16 |
| July 3rd 2024 | H.C. Wainwright | Initiation | Buy | $15 |
| May 30th 2024 | Stifel | Initiation | Buy | $21 |
Earnings History & Surprises
ABEOBeat Rate
56%
Last 18 quarters
Avg Surprise
+44.5%
EPS vs Estimate
Beats / Misses
10/6
2 met exactly
Latest EPS
$-0.10
Q4 2025
EPS Surprise History
Q1 24
-25.5%
$-0.64vs$-0.51
Q2 24
-12.8%
$-0.53vs$-0.47
Q3 24
-127.3%
$-0.75vs$-0.33
Q4 24
+18.4%
$-0.31vs$-0.38
Q1 25
+44.2%
$-0.24vs$-0.43
Q2 25
+31.4%
$-0.24vs$-0.35
Q3 25
+538.5%
$1.71vs$-0.39
Q4 25
+63.0%
$-0.10vs$-0.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.33 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.27 | $-0.10 | +63.0% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.39 | $1.71 | +538.5% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.35 | $-0.24 | +31.4% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-0.43 | $-0.24 | +44.2% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.38 | $-0.31 | +18.4% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.33 | $-0.75 | -127.3% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.47 | $-0.53 | -12.8% | ✗ MISS |
Q1 2024 | Mar 18, 2024 | $-0.51 | $-0.64 | -25.5% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.53 | $-0.48 | +9.4% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.66 | $-0.44 | +33.3% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.58 | $-0.54 | +6.9% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | $-0.75 | $1.53 | +304.0% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-1.78 | $-1.48 | +16.9% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-1.25 | $-2.08 | -66.4% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-2.00 | $-2.50 | -25.0% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-3.25 | $-3.50 | -7.7% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-4.00 | $-4.00 | 0.0% | = MET |
Q3 2021 | Jul 28, 2021 | $-4.00 | $-4.00 | 0.0% | = MET |
Latest News
Abeona Therapeutics Announces First Commercial Patient Treatment With FDA-Approved ZEVASKYN Gene Therapy For RDEB Wounds At Lucile Packard Children's Hospital Stanford
📈 PositiveBenzinga•Dec 8, 2025, 12:34 PM
Abeona Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.
📈 PositiveBenzinga•Nov 12, 2025, 04:52 PM
Abeona Therapeutics Q3 EPS $(0.10) Beats $(0.29) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 12:31 PM
Abeona Secures Permanent CMS J-Code J3389 For ZEVASKYN Gene Therapy In Recessive Dystrophic Epidermolysis Bullosa; New J-Code Becomes Effective January 1, 2026
📈 PositiveBenzinga•Oct 30, 2025, 02:48 PM
Abeona Therapeutics Announced That Its ABO-503 Gene Therapy For X-linked Retinoschisis Has Been Selected To Participate In FDA Rare Disease Endpoint Advancement Pilot Program
📈 PositiveBenzinga•Oct 13, 2025, 11:34 AM
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
📈 PositiveBenzinga•Oct 13, 2025, 11:18 AM
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
📈 PositiveBenzinga•Aug 18, 2025, 11:08 AM
Abeona Posts Q2 Profit on Asset Sale
📈 PositiveThe Motley Fool•Aug 14, 2025, 11:45 AM
Abeona sells Rare Pediatric Disease PRV for $155M
📈 PositiveSeeking Alpha•Jul 2, 2025, 03:47 PM
Abeona spikes on FDA nod for gene therapy
📈 PositiveSeeking Alpha•Apr 29, 2025, 10:40 AM
Frequently Asked Questions about ABEO
What is ABEO's current stock price?
Abeona Therapeutics Inc. (ABEO) is currently trading at $5.11 per share. The stock has moved +3.86% today.
What is the analyst price target for ABEO?
The average analyst price target for ABEO is $18.00, based on 1 analyst.
What sector is Abeona Therapeutics Inc. in?
Abeona Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ABEO's market cap?
Abeona Therapeutics Inc. has a market capitalization of $0.26 billion, making it a small-cap company.
Does ABEO pay dividends?
No, Abeona Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
ASMB
Assembly Biosciences, Inc.
$35.26
Mkt Cap: $0.3B
ELDN
Eledon Pharmaceuticals, Inc.
$1.64
Mkt Cap: $0.1B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
PBYI
Puma Biotechnology, Inc.
$5.63
Mkt Cap: $0.3B
SGMT
Sagimet Biosciences Inc.
$6.28
Mkt Cap: $0.2B
TNYA
Tenaya Therapeutics, Inc.
$0.70
Mkt Cap: $0.1B
VYGR
Voyager Therapeutics, Inc.
$4.00
Mkt Cap: $0.2B
Explore stocks similar to ABEO for comparison